ARAY
Accuray Incorporated
ARAY offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over ARAY overall, supported by stronger fundamentals and lower modeled downside.
ARAY Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Weak |
ARAY's revenue, profitability, cash flow and balance sheet are all currently under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARAY PE Valuation
ARAY has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ARAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect ARAY's losses to shrink, with revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ARAY on the outlook, with more favorable revenue expectations.
ARAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.00 | +$0.40 |
| Q2 2026 | -$16.00 | -$15.20 |
| Q1 2026 | -$14.80 | -$14.80 |
| Q4 2025 | -$11.60 | -$9.60 |
| Q3 2025 | -$6.40 | +$0.40 |
| Q2 2025 | -$0.80 | +$5.60 |
| Q1 2025 | $0.00 | +$8.80 |
| Q4 2024 | -$2.00 | +$4.00 |
ARAY lost $6.00 per share over the past year, about the same as its loss the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ARAY on earnings quality, reporting a profit while its opponent remains loss making.
ARAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $86.5M | -7.9% |
| Q2 2026 | $100.9M | -21% |
| Q1 2026 | $104.8M | -7.4% |
| Q4 2025 | $102.2M | -12% |
| Q3 2025 | $93.9M | -7.5% |
| Q2 2025 | $127.5M | -5% |
| Q1 2025 | $113.2M | +12% |
| Q4 2024 | $116.2M | +8.3% |
ARAY's revenue has slid since its 2024 peak: $87M last quarter, down 7.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -42% | -30 points |
| Q2 2026 | 5.5% | +2.1 points |
| Q1 2026 | -8.7% | -9.6 points |
| Q4 2025 | -11% | -15 points |
| Q3 2025 | -12% | -9.9 points |
| Q2 2025 | 3.3% | -1.8 points |
| Q1 2025 | 0.9% | +5.4 points |
| Q4 2024 | 4% | +7.8 points |
ARAY's operating margin was −42% last quarter, down 30 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ARAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ARAY on profitability, with a higher operating margin.
ARAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.9M | -138% |
| Q2 2026 | $2M | +$13M |
| Q1 2026 | -$6.1M | -136% |
| Q4 2025 | -$19M | -2151% |
| Q3 2025 | $10.3M | +$18.7M |
| Q2 2025 | -$11M | -217% |
| Q1 2025 | $17.1M | +$26M |
| Q4 2024 | $927K | +$7.3M |
ARAY's free cash flow was −$27M over the past year, against $17M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ARAY on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +14% | +416K shares |
| 1 year | +35% | +911K shares |
| 3 years | +43% | +1M shares |
| 5 years | +50% | +1.2M shares |
| Available history | +54% | +1.2M shares |
ARAY has 3M diluted shares, up 35% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over ARAY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ARAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 17.8x | High |
| Q2 2025 | 6.6x | High |
| Q1 2025 | 6.3x | High |
| Q4 2024 | 11.1x | High |
| Q3 2024 | 52.6x | High |
| Q2 2024 | 17.4x | High |
| Q4 2023 | 21.3x | High |
| Q3 2023 | 9.3x | High |
ARAY's net debt is about 18 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ARAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.4 | Oversold |
| Stochastic | 3.2 | Oversold |
ARAY's weekly RSI is 26 (oversold) and its Stochastic is 3 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ARAY PE vs Healthcare Sector
| Metric | ARAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARAY has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ARAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.69 | 54% below |
| 20 week MA | $8.94 | 66% below |
| 50 week MA | $16.9 | 82% below |
| 100 week MA | $40.9 | 92% below |
| 200 week MA | $72.4 | 96% below |
ARAY is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ARAY on trend strength, trading above more of its moving averages.
ARAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $112.8 | $177.2 | +57% |
| 2021 | $177.2 | $195.6 | +10% |
| 2022 | $195.6 | $79.2 | -60% |
| 2023 | $79.2 | $113.2 | +43% |
| 2024 | $113.2 | $73.2 | -35% |
| 2025 | $73.2 | $33.0 | -55% |
| 2026 YTD | $33.0 | $3.08 | -91% |
ARAY has finished lower in three of the last six years. It's down 91% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ARAY on returns for 2026, with the stronger performance.